Clinic
Doctors Hospital of Laredo
Doctors Hospital of Laredo was paid $52.31M by Medicaid between Mar 2019 and Dec 2024, across 211 billing codes. Its largest line is 99284, emergency room visit (serious) — 49% of everything it billed.
33Billing provider infoDOCTORS HOSPITAL OF LAREDO
LAREDO, TX 78045
LAREDO, TX 78045
33aNPI1396731105assigned 09/27/2005
33bProvider typeAmbulatory Surgical Clinic/Center
28Total paid$52.31M
24GClaims807,477
24DCodes billed211
24AFirst – last monthMar 2019 – Dec 2024
Compared with peers
Next to other Ambulatory Surgical Clinic/Center providers in Texas
Rank by total paid#9 of 320
Median peer was paid$205K
This provider vs. median255×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official FILTON, STEVE controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2019 | 1,137 | $42K | |
| 2020 | 22,669 | $1.89M | |
| 2021 | 153,484 | $8.24M | |
| 2022 | 227,177 | $12.29M | |
| 2023 | 258,540 | $18.57M | |
| 2024incomplete | 144,470 | $11.28M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 49% | 50,199 | 47,969 | $25.65M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 22% | 16,679 | 15,769 | $11.27M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 4.7% | 37,986 | 36,892 | $2.47M |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | 2.8% | 29,142 | 28,270 | $1.45M |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 2.6% | 3,596 | 3,430 | $1.37M |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | 2.5% | 55,691 | 34,995 | $1.31M |
| 87430 | 1.5% | 32,264 | 31,292 | $776K | |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | 1.1% | 27,494 | 26,456 | $575K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 9,261 | 8,981 | $451K |
| 87420 | <1% | 19,521 | 18,995 | $416K | |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 48,670 | 45,083 | $391K |
| 80053 | Comprehensive metabolic panel | <1% | 37,388 | 34,723 | $383K |
199 more codes
| 71045 | Radiologic examination, chest; single view | <1% | 11,772 | $373K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 5,358 | $354K |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 8,261 | $340K |
| 87070 | <1% | 27,955 | $340K | |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 2,644 | $312K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 3,984 | $270K |
| 59025 | Fetal non-stress test | <1% | 2,041 | $233K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 1,123 | $179K |
| 80061 | Lipid panel | <1% | 12,301 | $167K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 10,643 | $166K |
| 81001 | <1% | 45,897 | $166K | |
| 74018 | <1% | 3,328 | $148K | |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 1,917 | $123K |
| 76801 | <1% | 1,051 | $121K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 11,659 | $120K |
| 83525 | <1% | 7,395 | $116K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 4,853 | $103K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 3,599 | $93K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 11,674 | $92K |
| 81025 | <1% | 7,858 | $83K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 9,215 | $79K |
| 83690 | <1% | 10,498 | $74K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 6,168 | $74K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 3,639 | $68K |
| 80050 | General health panel | <1% | 804 | $59K |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 940 | $52K |
| 82977 | <1% | 5,202 | $52K | |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 1,010 | $49K |
| G0378 | Hospital observation service, per hour | <1% | 119 | $48K |
| 84436 | <1% | 5,081 | $45K | |
| 80076 | <1% | 4,345 | $44K | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 674 | $36K |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | <1% | 142 | $36K |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 555 | $34K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 1,562 | $33K |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 1,266 | $33K |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 9,213 | $31K |
| 87186 | <1% | 4,772 | $30K | |
| 74019 | <1% | 519 | $30K | |
| 73610 | <1% | 565 | $28K | |
| 86703 | <1% | 1,707 | $27K | |
| 84484 | <1% | 5,239 | $27K | |
| 83880 | <1% | 2,126 | $26K | |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 768 | $25K |
| 84481 | <1% | 1,088 | $25K | |
| 72082 | <1% | 214 | $24K | |
| 84702 | <1% | 1,646 | $24K | |
| S0164 | Injection, pantoprazole sodium, 40 mg | <1% | 338 | $23K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 906 | $23K |
| 84460 | <1% | 3,043 | $22K | |
| 86850 | <1% | 897 | $22K | |
| 84450 | <1% | 3,042 | $22K | |
| 86003 | <1% | 624 | $20K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 575 | $20K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 578 | $20K |
| U0001 | Cdc 2019 novel coronavirus (2019-ncov) real-time rt-pcr diagnostic panel | <1% | 379 | $19K |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 767 | $19K |
| 83655 | <1% | 1,122 | $19K | |
| 87077 | <1% | 3,159 | $18K | |
| 73630 | <1% | 503 | $18K | |
| 84439 | <1% | 2,811 | $18K | |
| 74022 | <1% | 208 | $18K | |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 84 | $17K |
| 83605 | <1% | 2,267 | $17K | |
| 85027 | <1% | 4,160 | $17K | |
| 81002 | <1% | 4,467 | $16K | |
| 85610 | <1% | 5,445 | $15K | |
| 82550 | <1% | 2,970 | $15K | |
| 70260 | <1% | 190 | $14K | |
| 73130 | <1% | 313 | $14K | |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 109 | $12K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 210 | $12K |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 2,490 | $11K |
| 71250 | <1% | 152 | $11K | |
| 87040 | <1% | 1,882 | $11K | |
| 73564 | <1% | 291 | $11K | |
| 0353U | <1% | 284 | $10K | |
| 72100 | <1% | 259 | $9K | |
| 85730 | <1% | 3,114 | $9K | |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 301 | $9K |
| 87209 | <1% | 378 | $9K | |
| 0202U | Oncology (prostate), multianalyte, gene expression profiling | <1% | 6,302 | $9K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 156 | $7K |
| 73030 | <1% | 325 | $7K | |
| 66984 | Extracapsular cataract removal with insertion of intraocular lens prosthesis | <1% | 175 | $7K |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 1,821 | $7K |
| 83735 | <1% | 2,210 | $6K | |
| 82248 | <1% | 1,186 | $6K | |
| 87899 | <1% | 476 | $6K | |
| 84703 | <1% | 765 | $6K | |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 43 | $5K |
| 97163 | <1% | 76 | $5K | |
| 87425 | <1% | 320 | $5K | |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 14 | $5K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 115 | $5K |
| 82247 | <1% | 846 | $5K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 69,854 | $5K |
| 82150 | <1% | 799 | $5K | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 193 | $5K |
| 82728 | <1% | 1,025 | $5K | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 145 | $5K |
| 87177 | <1% | 378 | $5K | |
| 87045 | <1% | 360 | $5K | |
| 83630 | <1% | 156 | $4K | |
| 86592 | <1% | 1,036 | $4K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 78 | $4K |
| 87581 | <1% | 142 | $4K | |
| 87486 | <1% | 142 | $4K | |
| 86901 | <1% | 1,730 | $4K | |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 61 | $4K |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 781 | $4K |
| 82607 | <1% | 1,311 | $4K | |
| 90715 | <1% | 128 | $4K | |
| 86900 | <1% | 1,559 | $4K | |
| 70360 | <1% | 60 | $4K | |
| 87260 | <1% | 170 | $3K | |
| 73110 | <1% | 68 | $3K | |
| 87279 | <1% | 129 | $3K | |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 1,810 | $3K |
| 83550 | <1% | 806 | $3K | |
| 70486 | <1% | 16 | $2K | |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | <1% | 105 | $2K |
| 83540 | <1% | 1,027 | $2K | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 1,356 | $2K |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 487 | $2K |
| J2543 | Injection, piperacillin sodium/tazobactam sodium, 1 gram/0.125 grams (1.125 grams) | <1% | 56 | $2K |
| 85379 | <1% | 291 | $2K | |
| 82270 | <1% | 632 | $2K | |
| 86677 | <1% | 151 | $2K | |
| 86140 | <1% | 506 | $2K | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 422 | $2K |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 12 | $2K |
| 87340 | <1% | 154 | $1K | |
| 83970 | <1% | 175 | $1K | |
| C9113 | Injection, pantoprazole sodium, per vial | <1% | 113 | $1K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 1,870 | $1K |
| 76770 | <1% | 12 | $1K | |
| 85245 | <1% | 39 | $1K | |
| 85246 | <1% | 39 | $1K | |
| 85247 | <1% | 39 | $1K | |
| 82553 | <1% | 273 | $1K | |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 13 | $1K |
| 82570 | <1% | 1,076 | $1K | |
| 86762 | <1% | 81 | $1K | |
| 80069 | <1% | 906 | $1K | |
| 85652 | <1% | 791 | $1K | |
| 82043 | <1% | 993 | $977.91 | |
| 72131 | <1% | 12 | $886.10 | |
| 82951 | <1% | 67 | $882.83 | |
| 87338 | <1% | 37 | $750.43 | |
| 73090 | <1% | 15 | $717.77 | |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 133 | $704.52 |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 1,274 | $699.01 |
| 83986 | <1% | 134 | $686.74 | |
| 72040 | <1% | 12 | $625.66 | |
| 82947 | <1% | 111 | $594.45 | |
| 73502 | <1% | 27 | $550.24 | |
| 87653 | <1% | 17 | $543.30 | |
| 84145 | <1% | 43 | $481.38 | |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 1,400 | $453.32 |
| 82542 | <1% | 13 | $365.65 | |
| 82746 | <1% | 134 | $355.63 | |
| 84156 | <1% | 351 | $349.75 | |
| 73700 | <1% | 13 | $339.93 | |
| 73562 | <1% | 13 | $329.56 | |
| 80074 | <1% | 13 | $327.69 | |
| 87210 | <1% | 57 | $321.57 | |
| 82378 | <1% | 28 | $307.03 | |
| 82785 | <1% | 12 | $289.93 | |
| 73080 | <1% | 12 | $270.56 | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 4,737 | $270.25 |
| J0360 | Injection, hydralazine hcl, up to 20 mg | <1% | 28 | $262.43 |
| 87324 | <1% | 19 | $228.44 | |
| 77080 | <1% | 51 | $209.43 | |
| 84550 | <1% | 147 | $134.35 | |
| 82272 | <1% | 32 | $122.37 | |
| 86803 | <1% | 14 | $108.47 | |
| 84479 | <1% | 25 | $107.63 | |
| 84153 | <1% | 84 | $87.22 | |
| 82565 | <1% | 36 | $60.36 | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 47 | $50.90 |
| J2003 | Injection, lidocaine hydrochloride, 1 mg | <1% | 82 | $48.62 |
| 85018 | <1% | 13 | $43.31 | |
| 84100 | <1% | 28 | $41.30 | |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | <1% | 118 | $35.20 |
| J7510 | Prednisolone oral, per 5 mg | <1% | 181 | $23.35 |
| J2470 | Injection, pantoprazole sodium, 40 mg | <1% | 87 | $20.12 |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | <1% | 47 | $19.38 |
| 84520 | <1% | 12 | $11.25 | |
| 87081 | <1% | 85 | $9.70 | |
| 82962 | <1% | 2,952 | $6.60 | |
| J2704 | Injection, propofol, 10 mg | <1% | 854 | $2.88 |
| A9270 | Non-covered item or service | 0% | 3,733 | $0.00 |
| 88342 | 0% | 29 | $0.00 | |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | 0% | 13 | $0.00 |
| L3650 | Shoulder orthosis, figure of eight design abduction restrainer, prefabricated, off-the-shelf | 0% | 41 | $0.00 |
| 88313 | 0% | 14 | $0.00 | |
| 99152 | 0% | 15 | $0.00 | |
| C1780 | Lens, intraocular (new technology) | 0% | 40 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialFILTON, STEVE (CFO, SENIOR VP)
| Provider | Location | Paid |
|---|---|---|
| District Hospital Partners L P | Washington, DC | $136.25M |
| Mcallen Hospitals L P | Edinburg, TX | $124.61M |
| Lancaster Hospital Corporation | Palmdale, CA | $108.63M |
| Universal Health Services of Rancho Springs INC | Murrieta, CA | $61.95M |
| Valley Hospital Medical Center | Las Vegas, NV | $47.03M |
| Northwest Texas Healthcare System INC | Amarillo, TX | $44.81M |
| Uhs of Bowling Green LLC | Bowling Green, KY | $41.21M |
| Uhs-Corona INC | Corona, CA | $35.18M |
| Spring Valley Medical Center | Las Vegas, NV | $33.58M |
| Aiken Regional Medical Centers LLC | Aiken, SC | $31.51M |
| Summerlin Hospital Medical Center L L C | Las Vegas, NV | $30.26M |
| Manatee Memorial Hospital L P | Bradenton, FL | $22.33M |
| Desert Springs Hospital | Las Vegas, NV | $22.29M |
| Fort Duncan Medical Center LP | Eagle Pass, TX | $15.80M |
| Psi Pride Institute INC | Eden Prairie, MN | $15.57M |
| Uhs of Fuller INC | S Attleboro, MA | $13.47M |
| Uhs of Texoma, INC | Denison, TX | $12.51M |
| Arbour INC | Boston, MA | $12.36M |
| Wellington Regional Medical Center LLC | Wellington, FL | $10.75M |
| Friends Behavioral Health System, LP | Philadelphia, PA | $9.55M |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.